126 related articles for article (PubMed ID: 28967708)
1. Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacological Effect of Orally Administered CORT125134: An Adaptive, Double-Blind, Randomized, Placebo-Controlled Phase 1 Clinical Study.
Hunt H; Donaldson K; Strem M; Zann V; Leung P; Sweet S; Connor A; Combs D; Belanoff J
Clin Pharmacol Drug Dev; 2018 May; 7(4):408-421. PubMed ID: 28967708
[TBL] [Abstract][Full Text] [Related]
2. Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.
Richard M; Kaufmann P; Ort M; Kornberger R; Dingemanse J
CNS Drugs; 2020 Mar; 34(3):311-323. PubMed ID: 31994022
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects.
Muirhead GJ; Osterloh IH; Whaley S; van den Berg F
J Sex Med; 2019 Feb; 16(2):213-222. PubMed ID: 30612858
[TBL] [Abstract][Full Text] [Related]
4. First-in-man study of ACT-709478, a novel selective triple T-type calcium channel blocker.
Richard M; Kaufmann P; Kornberger R; Dingemanse J
Epilepsia; 2019 May; 60(5):968-978. PubMed ID: 31004346
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, Safety, and Tolerability of Single- and Multiple-Dose Once-Daily Baricitinib in Healthy Chinese Subjects: A Randomized Placebo-Controlled Study.
Zhao X; Sheng XY; Payne CD; Zhang X; Wang F; Cui YM
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):952-960. PubMed ID: 32945153
[TBL] [Abstract][Full Text] [Related]
6. Tolerability, pharmacokinetics, and pharmacodynamics of single-dose almorexant, an orexin receptor antagonist, in healthy elderly subjects.
Hoever P; Hay J; Rad M; Cavallaro M; van Gerven JM; Dingemanse J
J Clin Psychopharmacol; 2013 Jun; 33(3):363-70. PubMed ID: 23609389
[TBL] [Abstract][Full Text] [Related]
7. Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10-2474: A Double-Blind, Randomized, Placebo-Controlled Study in Healthy Volunteers.
Rocha JF; Santos A; Gama H; Moser P; Falcão A; Pressman P; Wallace Hayes A; Soares-da-Silva P
Clin Pharmacol Ther; 2022 Feb; 111(2):391-403. PubMed ID: 33998672
[TBL] [Abstract][Full Text] [Related]
8. Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers.
Weisel K; Scott NE; Tompson DJ; Votta BJ; Madhavan S; Povey K; Wolstenholme A; Simeoni M; Rudo T; Richards-Peterson L; Sahota T; Wang JG; Lich J; Finger J; Verticelli A; Reilly M; Gough PJ; Harris PA; Bertin J; Wang ML
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226626
[TBL] [Abstract][Full Text] [Related]
9. Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in healthy Korean male volunteers: single- and multiple-dose randomized, placebo-controlled studies.
Kim TE; Gu N; Yoon SH; Cho JY; Park KM; Shin SG; Jang IJ; Yu KS
Clin Ther; 2012 Feb; 34(2):482-94. PubMed ID: 22284902
[TBL] [Abstract][Full Text] [Related]
10. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
11. Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study.
Takahashi S; Fujiwara Y; Nakano K; Shimizu T; Tomomatsu J; Koyama T; Ogura M; Tachibana M; Kakurai Y; Yamashita T; Sakajiri S; Yamamoto N
Cancer Sci; 2021 Jun; 112(6):2361-2370. PubMed ID: 33686772
[TBL] [Abstract][Full Text] [Related]
12. Safety, Tolerability and Pharmacokinetics of FAAH Inhibitor V158866: A Double-Blind, Randomised, Placebo-Controlled Phase I Study in Healthy Volunteers.
Pawsey S; Wood M; Browne H; Donaldson K; Christie M; Warrington S
Drugs R D; 2016 Jun; 16(2):181-91. PubMed ID: 26987975
[TBL] [Abstract][Full Text] [Related]
13. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis.
Banfield C; Scaramozza M; Zhang W; Kieras E; Page KM; Fensome A; Vincent M; Dowty ME; Goteti K; Winkle PJ; Peeva E
J Clin Pharmacol; 2018 Apr; 58(4):434-447. PubMed ID: 29266308
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, Safety, and Tolerability of Selonsertib, an Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitor, Following First-in-Human Single and Multiple Ascending Doses in Healthy Subjects.
Nelson CH; Etchevers K; Yi S; Breckenridge D; Hepner M; Patel U; Ling J; Mathias A
Clin Pharmacokinet; 2020 Sep; 59(9):1109-1117. PubMed ID: 32333325
[TBL] [Abstract][Full Text] [Related]
15. FKBP5 mRNA Expression Is a Biomarker for GR Antagonism.
Bali U; Phillips T; Hunt H; Unitt J
J Clin Endocrinol Metab; 2016 Nov; 101(11):4305-4312. PubMed ID: 27459525
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of pimecrolimus, a novel nonsteroid anti-inflammatory drug, after single and multiple oral administration.
Scott G; Osborne SA; Greig G; Hartmann S; Ebelin ME; Burtin P; Rappersberger K; Komar M; Wolff K
Clin Pharmacokinet; 2003; 42(14):1305-14. PubMed ID: 14606933
[TBL] [Abstract][Full Text] [Related]
17. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers.
Addy C; Rothenberg P; Li S; Majumdar A; Agrawal N; Li H; Zhong L; Yuan J; Maes A; Dunbar S; Cote J; Rosko K; Van Dyck K; De Lepeleire I; de Hoon J; Van Hecken A; Depré M; Knops A; Gottesdiener K; Stoch A; Wagner J
J Clin Pharmacol; 2008 Jun; 48(6):734-44. PubMed ID: 18508950
[TBL] [Abstract][Full Text] [Related]
18. Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers.
Turncliff R; DiPetrillo L; Silverman B; Ehrich E
Clin Ther; 2015 Feb; 37(2):338-48. PubMed ID: 25456560
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers.
Pieniaszek HJ; Sy SK; Ebling W; Fossler MJ; Cain VA; Mondick JT; Ma S; Kornhauser DM
J Clin Pharmacol; 2002 Jul; 42(7):738-53. PubMed ID: 12092741
[TBL] [Abstract][Full Text] [Related]
20. Multiple-dose pharmacokinetics, pharmacodynamics and tolerability of the oral ET(A) endothelin-receptor antagonist SPP301 in man.
Dieterle W; Mann J; Kutz K
Int J Clin Pharmacol Ther; 2005 Apr; 43(4):178-86. PubMed ID: 15966464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
